Tirzepatide
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Phase 2 · Completed · Enrollment 367
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| LY3841136 Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 1 + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 3 + Tirzepatide Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |